EnglishIntroduction: Pazopanib, a multi-target tyrosine-kinase inhibitor (TKI), is a relatively novel anticancer agent registered for advanced renal cell carcinoma recently emerged in the setting of advanced soft-tissue sarcoma (STS). In the early clinical trials pazopanib has been very marginally linked to left ventricular ejection fraction (LVEF) dysfunction as, on contrary, reported for other anti-angiogenesis TKIs, such as Sunitinib and Sorafenib. Presentation of Case: We here present a case of severe, but reversible, congestive cardiac failure in a 37-year old Caucasian man affected by soft-tissue sarcoma during an efficacious treatment with pazopanib. Conclusion: Cardiac damage from novel TKI treatments is still an underestimated phenomenon. In our patient, pazopanib was the only treatment ensuring stability of disease and its discontinuation meant disease progression. Post-approval monitoring of novel TKIs should be taken into account by clinicians including a careful monitoring of LVEF and all symptoms suggestive of cardiac dysfunction, in particular for drugs potentially capable to change the natural history of still uncurable cancer.
Pazopanib-Induced Heart Failure in a Metastatic Sarcoma Patient: between Reversible Side Effect and Efficacy / Lucarini, Valeria; Madrigali, Stefano; Lugli, Roberta; Maur, Michela; Bertolini, Federica; Fontana, Annalisa; Masini, Cristina; Guarneri, Valentina; Conte, Pierfranco; Dominici, Massimo. - In: AMERICAN JOURNAL OF CANCER CASE REPORTS. - ISSN 2572-5742. - ELETTRONICO. - 2:2(2014), pp. 1-7.
| Data di pubblicazione: | 2014 | |
| Titolo: | Pazopanib-Induced Heart Failure in a Metastatic Sarcoma Patient: between Reversible Side Effect and Efficacy | |
| Autore/i: | Lucarini, Valeria; Madrigali, Stefano; Lugli, Roberta; Maur, Michela; Bertolini, Federica; Fontana, Annalisa; Masini, Cristina; Guarneri, Valentina; Conte, Pierfranco; Dominici, Massimo | |
| Autore/i UNIMORE: | ||
| Rivista: | AMERICAN JOURNAL OF CANCER CASE REPORTS | |
| Volume: | 2 | |
| Fascicolo: | 2 | |
| Pagina iniziale: | 1 | |
| Pagina finale: | 7 | |
| Lingua: | Inglese | |
| Parole Chiave: | pazopanib; heart failure; sarcoma | |
| Abstract: | Introduction: Pazopanib, a multi-target tyrosine-kinase inhibitor (TKI), is a relatively novel anticancer agent registered for advanced renal cell carcinoma recently emerged in the setting of advanced soft-tissue sarcoma (STS). In the early clinical trials pazopanib has been very marginally linked to left ventricular ejection fraction (LVEF) dysfunction as, on contrary, reported for other anti-angiogenesis TKIs, such as Sunitinib and Sorafenib. Presentation of Case: We here present a case of severe, but reversible, congestive cardiac failure in a 37-year old Caucasian man affected by soft-tissue sarcoma during an efficacious treatment with pazopanib. Conclusion: Cardiac damage from novel TKI treatments is still an underestimated phenomenon. In our patient, pazopanib was the only treatment ensuring stability of disease and its discontinuation meant disease progression. Post-approval monitoring of novel TKIs should be taken into account by clinicians including a careful monitoring of LVEF and all symptoms suggestive of cardiac dysfunction, in particular for drugs potentially capable to change the natural history of still uncurable cancer. | |
| Citazione: | Pazopanib-Induced Heart Failure in a Metastatic Sarcoma Patient: between Reversible Side Effect and Efficacy / Lucarini, Valeria; Madrigali, Stefano; Lugli, Roberta; Maur, Michela; Bertolini, Federica; Fontana, Annalisa; Masini, Cristina; Guarneri, Valentina; Conte, Pierfranco; Dominici, Massimo. - In: AMERICAN JOURNAL OF CANCER CASE REPORTS. - ISSN 2572-5742. - ELETTRONICO. - 2:2(2014), pp. 1-7. | |
| Tipologia | Articolo su rivista |
File in questo prodotto:
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
Copyright © 2022